This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.
| Registry number | NCT06260722 |
|---|---|
| Status | Active not recruiting |
| Phase | Phase 3 |
| Sponsor | Eli Lilly and Company |
| Enrollment | 1,250 participants |
| Design | Interventional, Randomized, Parallel, Masking: None |
| Conditions | Diabetes Mellitus, Type 2 |
| Interventions | Retatrutide; Semaglutide |
| Start | Feb 21, 2024 |
| Primary completion | Aug 27, 2026 |
| Study completion | Feb 2027 |
| Results posted | Not yet |
| Registry last updated | Sep 28, 2026 |
Compounds on this site that cite this trial
What the registry says the trial is about
The purpose of this study is to investigate the efficacy and safety of retatrutide compared with semaglutide in participants with Type 2 Diabetes and inadequate glycemic control with metformin with or without sodium-glucose cotransporter-2 inhibitor (SGLT2i). The study will last about 26 months and may include up to 24 visits.
Primary outcomes
These are what the trial was designed to measure first. They are registered in advance, which is what makes a later result checkable.
| Outcome measure | Time frame |
|---|---|
| Change from Baseline in Hemoglobin A1c (HbA1c) (%) | Baseline, Week 80 |
12 secondary outcomes also registered. See the registry record for the full list.
Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Nov 17, 2026. See the trial changes feed for what has changed recently.
More trials of Retatrutide
- TRANSCEND-T2D-1: Retatrutide, Phase 3 (NCT06354660)
- Retatrutide: Phase 3 Trial (NCT05929079)
- Retatrutide: Phase 2 Trial (NCT05936151)
- Retatrutide and Dulaglutide: Phase 2 Trial (NCT04867785)
- Retatrutide: Phase 3 Trial in Obesity (NCT07357415)
- Retatrutide: Phase 3 Trial in Obesity (NCT05931367)
Research area: Metabolic and incretin. Every registered trial we follow is in the clinical trial tracker, and the labels used on this page are explained in our evidence standards.